Materias dentro de su búsqueda.
Mostrando 83,701 - 83,720 Resultados de 84,353 Para Buscar '"HR"', tiempo de consulta: 0.87s Limitar resultados
  1. 83701
    “…In the acute and subacute stage, the typical sign detection of intramural hematoma and Grade II enhancement revealed by HR-MRI was higher than the observations in the chronic stage (P = 0.000/0.000/0.016), while there was no significant difference by MRA (P = 0.902). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Imaging investigation of cervicocranial artery dissection by using high resolution magnetic resonance VWI and MRA: qualitative and quantitative analysis at different stages
  2. 83702
    “…The age and sex adjusted hazard ratio (adjHR) was 0.75 (95% CI = 0.36–1.55). The results remained robust in sensitivity analyses excluding participants without anticoagulants. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Association of statin use and lipid levels with cerebral microbleeds and intracranial hemorrhage in patients with atrial fibrillation: A prospective cohort study
  3. 83703
    “…In multivariate analysis, prior PrEP use [HR (95% CI) = 2.2 (1.3-4.0)] was associated with PrEP initiation. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2896. Oral PrEP Uptake among HVTN 704/HPTN 085 Participants: Implications for the Future of Biomedical HIV Prevention Trials
  4. 83704
    “…[Figure: see text] [Figure: see text] [Figure: see text] CONCLUSION: There was a reduction in inadequate therapy prescribed once cultures were available (IET to IDT) overall and across each of the 12-hr TAT to susceptibility results periods evaluated in Carb-S and Carb-NS ENT and PSA positive cases. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1931. Real-world evaluation of adequacy of empiric and definitive therapy in carbapenem susceptible and non-susceptible Enterobacterales and Pseudomonas aeruginosa by time to culture result: A multicenter analysis
  5. 83705
    “…Weighted Cox proportional hazard regression was used to estimate hazard ratios (HR) and 95% CI of mortality risk. RESULTS: Overall, 1755 individuals (weighted mean [SE] age, 65.2 [0.5] years; 1047 men [weighted 58.5%]) with CHD were included, with geometric mean levels of serum MMA 182.4 nmol/L, serum B12 494.5 pg/ml, and dietary B12 intake 4.42 mg/day, and percentage of B12 supplements use 39.1%. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Methylmalonic acid, vitamin B12, and mortality risk in patients with preexisting coronary heart disease: a prospective cohort study
  6. 83706
    “…Polzar, H. Stephan, T. Crompton, H.R. MacDonald, H.G. Mannherz, and J. Tschopp. 1993. …”
    Enlace del recurso
    Enlace del recurso
    Texto
    Androgen Ablation Leads to an Upregulation and Intranuclear Accumulation of Deoxyribonuclease I in Rat Prostate Epithelial Cells Paralleling Their Apoptotic Elimination
  7. 83707
    Publicado 2008
    “…Photographic and patient self-assessments suggested lower rates of late adverse effects after 39 Gy than with 50 Gy, with an HR for late change in breast appearance (photographic) of 0·69 (95% CI 0·52–0·91, p=0·01). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial
  8. 83708
    “…Treatment with TPV/r, co-infection with hepatitis B and/or C, DAIDS grade >1 TE and CD4(+ )> 200 cells/mm(3 )at baseline were found to be independent risk factors for development of DAIDS Grade 3/4 TE; the hazard ratios (HR) were 2.8, 2.0, 2.1 and 1.5, respectively. Four of the 144 (2.7%) patients with Grade 3/4 TEs developed hepatic SAEs; overall, 14/1299 (1.1%) patients had hepatic SAEs including six with hepatic failure (0.5%). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Hepatic profile analyses of tipranavir in Phase II and III clinical trials
  9. 83709
    “…Median time to recovery was 2.31 days, (95% confidence interval [CI] 1.97–2.73) for the control group and 2.02 days (95% CI 1.96–2.34) for the intervention group, indicating no significant effect of physiotherapy (hazard ratio [HR]  = 1.09, 95% CI 0.91–1.31, p = 0.33). No treatment by age interaction was found (p = 0.97). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Effectiveness of Chest Physiotherapy in Infants Hospitalized with Acute Bronchiolitis: A Multicenter, Randomized, Controlled Trial
  10. 83710
    “…METHODS: Human retinal progenitor cells (HRPC) and human umbilical vein endothelial cells (HUVEC) were cultured/co-cultured under normoxia (control) (20% O(2)) or hypoxia (1% O(2)) condition for 24 hr. Controls were monolayer cultures of each cell type maintained alone. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Co-culture of Retinal and Endothelial Cells Results in the Modulation of Genes Critical to Retinal Neovascularization
  11. 83711
    “…Time to death did not differ (hazard ratio [HR] 0·94, 95% CI 0·76–1·15). In a preplanned subgroup analysis of patients with baseline CD4 counts of 201–350 cells per μL, mortality was slightly lower in the intervention group than in the control group (0·73, 0·54–1.00; p=0·052), but it did not differ between groups in patients with baseline CD4 of 200 cells per μL or less (0·94, 0·76–1·15; p=0·577). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Task shifting of antiretroviral treatment from doctors to primary-care nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial
  12. 83712
    por Li, Jingmei, Lindström, Linda S., Foo, Jia N., Rafiq, Sajjad, Schmidt, Marjanka K., Pharoah, Paul D. P., Michailidou, Kyriaki, Dennis, Joe, Bolla, Manjeet K., Wang, Qin, Van ‘t Veer, Laura J., Cornelissen, Sten, Rutgers, Emiel, Southey, Melissa C., Apicella, Carmel, Dite, Gillian S., Hopper, John L., Fasching, Peter A., Haeberle, Lothar, Ekici, Arif B., Beckmann, Matthias W., Blomqvist, Carl, Muranen, Taru A., Aittomäki, Kristiina, Lindblom, Annika, Margolin, Sara, Mannermaa, Arto, Kosma, Veli-Matti, Hartikainen, Jaana M., Kataja, Vesa, Chenevix-Trench, Georgia, Investigators, kConFab, Phillips, Kelly-Anne, McLachlan, Sue-Anne, Lambrechts, Diether, Thienpont, Bernard, Smeets, Ann, Wildiers, Hans, Chang-Claude, Jenny, Flesch-Janys, Dieter, Seibold, Petra, Rudolph, Anja, Giles, Graham G., Baglietto, Laura, Severi, Gianluca, Haiman, Christopher A., Henderson, Brian E., Schumacher, Fredrick, Le Marchand, Loic, Kristensen, Vessela, Alnæs, Grethe I. Grenaker, Borresen-Dale, Anne-Lise, Nord, Silje, Winqvist, Robert, Pylkäs, Katri, Jukkola-Vuorinen, Arja, Grip, Mervi, Andrulis, Irene L., Knight, Julia A., Glendon, Gord, Tchatchou, Sandrine, Devilee, Peter, Tollenaar, Robert, Seynaeve, Caroline, Hooning, Maartje, Kriege, Mieke, Hollestelle, Antoinette, van den Ouweland, Ans, Li, Yi, Hamann, Ute, Torres, Diana, Ulmer, Hans U., Rüdiger, Thomas, Shen, Chen-Yang, Hsiung, Chia-Ni, Wu, Pei-Ei, Chen, Shou-Tung, Teo, Soo Hwang, Taib, Nur Aishah Mohd, Har Yip, Cheng, Fuang Ho, Gwo, Matsuo, Keitaro, Ito, Hidemi, Iwata, Hiroji, Tajima, Kazuo, Kang, Daehee, Choi, Ji-Yeob, Park, Sue K., Yoo, Keun-Young, Maishman, Tom, Tapper, William J., Dunning, Alison, Shah, Mitul, Luben, Robert, Brown, Judith, Chuen Khor, Chiea, Eccles, Diana M., Nevanlinna, Heli, Easton, Douglas, Humphreys, Keith, Liu, Jianjun, Hall, Per, Czene, Kamila
    Publicado 2014
    “…Rs4458204_A near CCL20 (2q36.3) is found to be associated with breast cancer-specific death at a genome-wide significant level (n=2,641, 440 events, combined allelic hazard ratio (HR)=1.81 (1.49–2.19); P for trend=1.90 × 10(−9)). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy
  13. 83713
    por Deelen, Joris, Beekman, Marian, Uh, Hae-Won, Broer, Linda, Ayers, Kristin L., Tan, Qihua, Kamatani, Yoichiro, Bennet, Anna M., Tamm, Riin, Trompet, Stella, Guðbjartsson, Daníel F., Flachsbart, Friederike, Rose, Giuseppina, Viktorin, Alexander, Fischer, Krista, Nygaard, Marianne, Cordell, Heather J., Crocco, Paolina, van den Akker, Erik B., Böhringer, Stefan, Helmer, Quinta, Nelson, Christopher P., Saunders, Gary I., Alver, Maris, Andersen-Ranberg, Karen, Breen, Marie E., van der Breggen, Ruud, Caliebe, Amke, Capri, Miriam, Cevenini, Elisa, Collerton, Joanna C., Dato, Serena, Davies, Karen, Ford, Ian, Gampe, Jutta, Garagnani, Paolo, de Geus, Eco J.C., Harrow, Jennifer, van Heemst, Diana, Heijmans, Bastiaan T., Heinsen, Femke-Anouska, Hottenga, Jouke-Jan, Hofman, Albert, Jeune, Bernard, Jonsson, Palmi V., Lathrop, Mark, Lechner, Doris, Martin-Ruiz, Carmen, Mcnerlan, Susan E., Mihailov, Evelin, Montesanto, Alberto, Mooijaart, Simon P., Murphy, Anne, Nohr, Ellen A., Paternoster, Lavinia, Postmus, Iris, Rivadeneira, Fernando, Ross, Owen A., Salvioli, Stefano, Sattar, Naveed, Schreiber, Stefan, Stefánsson, Hreinn, Stott, David J., Tiemeier, Henning, Uitterlinden, André G., Westendorp, Rudi G.J., Willemsen, Gonneke, Samani, Nilesh J., Galan, Pilar, Sørensen, Thorkild I.A., Boomsma, Dorret I., Jukema, J. Wouter, Rea, Irene Maeve, Passarino, Giuseppe, de Craen, Anton J.M., Christensen, Kaare, Nebel, Almut, Stefánsson, Kári, Metspalu, Andres, Magnusson, Patrik, Blanché, Hélène, Christiansen, Lene, Kirkwood, Thomas B.L., van Duijn, Cornelia M., Franceschi, Claudio, Houwing-Duistermaat, Jeanine J., Slagboom, P. Eline
    Publicado 2014
    “…In a prospective meta-analysis (n = 34 103), the minor allele of rs2149954 (T) on chromosome 5q33.3 associates with increased survival (HR = 0.95, P = 0.003). This allele has previously been reported to associate with low blood pressure in middle age. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Genome-wide association meta-analysis of human longevity identifies a novel locus conferring survival beyond 90 years of age
  14. 83714
    por Aleksandrova, Krasimira, Pischon, Tobias, Jenab, Mazda, Bueno-de-Mesquita, H Bas, Fedirko, Veronika, Norat, Teresa, Romaguera, Dora, Knüppel, Sven, Boutron-Ruault, Marie-Christine, Dossus, Laure, Dartois, Laureen, Kaaks, Rudolf, Li, Kuanrong, Tjønneland, Anne, Overvad, Kim, Quirós, José Ramón, Buckland, Genevieve, Sánchez, María José, Dorronsoro, Miren, Chirlaque, Maria-Dolores, Barricarte, Aurelio, Khaw, Kay-Tee, Wareham, Nicholas J, Bradbury, Kathryn E, Trichopoulou, Antonia, Lagiou, Pagona, Trichopoulos, Dimitrios, Palli, Domenico, Krogh, Vittorio, Tumino, Rosario, Naccarati, Alessio, Panico, Salvatore, Siersema, Peter D, Peeters, Petra HM, Ljuslinder, Ingrid, Johansson, Ingegerd, Ericson, Ulrika, Ohlsson, Bodil, Weiderpass, Elisabete, Skeie, Guri, Borch, Kristin Benjaminsen, Rinaldi, Sabina, Romieu, Isabelle, Kong, Joyce, Gunter, Marc J, Ward, Heather A, Riboli, Elio, Boeing, Heiner
    Publicado 2014
    “…RESULTS: After accounting for study centre, age, sex and education, compared with 0 or 1 healthy lifestyle factors, the hazard ratio (HR) for CRC was 0.87 (95% confidence interval (CI): 0.44 to 0.77) for two factors, 0.79 (95% CI: 0.70 to 0.89) for three factors, 0.66 (95% CI: 0.58 to 0.75) for four factors and 0.63 (95% CI: 0.54 to 0.74) for five factors; P-trend <0.0001. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Combined impact of healthy lifestyle factors on colorectal cancer: a large European cohort study
  15. 83715
    “…At Cox Model, adjusted by gender, age, non-Italian origin, AIDS diagnosis, time on cART, number of regimens, CD4 nadir, baseline CD4, all the drugs had a positive effect on probability of failure (Figure), however the effect was significant for DRV/r (HR:0.21, 95% CI 0.07–0.59, p=0.03), ATV/r (0.30, 0.09–0.97, p=0.044) and RAL (0.37, 0.15–0.93, p=0.034); higher CD4 count at baseline was also associated with lower risk of failure while number of previous regimens with a higher risk. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis
  16. 83716
    “…Receiving a booster at age 10–14 years decreased HBsAg seroprevalence if participants were born to HBsAg-positive mothers (hazard ratio [HR] = 0.68, 95% CI 0.47–0.97). Limitations to consider in interpreting the study results include the small number of individuals with PLC, participants lost to follow-up, and the large proportion of participants who did not provide serum samples at follow-up. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Efficacy of Neonatal HBV Vaccination on Liver Cancer and Other Liver Diseases over 30-Year Follow-up of the Qidong Hepatitis B Intervention Study: A Cluster Randomized Controlled Trial
  17. 83717
    “…The median duration was 77.0 (IQR 29.0-152.3) days in the CAU group and 50.0 (IQR 20.8-99.0) days in the ECO group (hazard ratio [HR] 1.390, 95% CI 1.034-1.870, P=.03). No significant difference was found for duration until full RTW. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Effectiveness of a Blended Web-Based Intervention on Return to Work for Sick-Listed Employees With Common Mental Disorders: Results of a Cluster Randomized Controlled Trial
  18. 83718
    “…After a median follow-up of 24·2 months (IQR 21·9–29·5), progression-free survival was longer in the cediranib group (median 8·1 months [80% CI 7·4–8·8]) than in the placebo group (6·7 months [6·2–7·2]), with a hazard ratio (HR) of 0·58 (80% CI 0·40–0·85; one-sided p=0·032). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial
  19. 83719
    “…Co‐primary pharmacodynamic endpoints were 0–24‐hour weighted mean serum cortisol level on day 7 (cortisol(0–24 hr, Day 7)), and 0–4‐hour weighted mean and maximum QTcF and weighted mean and minimum serum potassium level on days 1 and 7. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Pharmacodynamics and Pharmacokinetics of Fluticasone Furoate/Vilanterol in Healthy Chinese Subjects
  20. 83720
    “…Among 318 patients who did initiate ART within 90 d, the hazard of attrition within the first 10 mo did not differ between the treatment arms (hazard ratio [HR] 1.06; 95% CI 0.61–1.84). The study was limited by the small number of sites and small sample size, and the generalizability of the results to other settings and to non-research conditions is uncertain. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Initiating Antiretroviral Therapy for HIV at a Patient’s First Clinic Visit: The RapIT Randomized Controlled Trial
Herramientas de búsqueda: RSS